Regulatory milestones

Biogen Idec Inc. (NASDAQ:BIIB) was up $7.15 to $230.27 on Friday after FDA accepted a BLA and EMA accepted an MAA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS). The company submitted the BLA in May. The PDUFA date is not disclosed. Biogen Idec gained $3.93 on the week.